Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 4, 2012, Pages 943-947

  Muscal, Jodi A ^a   Sun, Yongkai ^b   Nuchtern, Jed G ^a   Dauser, Robert C ^a   McGuffey, Leticia H ^a   Gibson, Brian W ^a   Berg, Stacey L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b CELGENE CORPORATION   (United States)

Author keywords

CSF penetration; Lenalidomide; Nonhuman primates; Pharmacokinetics; Thalidomide

Indexed keywords

LENALIDOMIDE; THALIDOMIDE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PENETRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; TANDEM MASS SPECTROMETRY;

ANIMALS; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; MACACA MULATTA; MALE; THALIDOMIDE;

EID: 84859799951     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1781-y     Document Type: Article

References (28)

1. Arora RS, Alston RD, Eden TO, Estlin EJ, Moran A, Birch JM (2009) Age-incidence patterns of primary CNS tumors in children, adolescents, and adults in England. Neuro Oncol 11(4):403-413
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58(2):71-96 (Pubitemid 351521864)
3. Wisoff JH, Boyett JM, Berger MS, Brant C, Li H, Yates AJ, McGuire-Cullen P, Turski PA, Sutton LN, Allen JC, Packer RJ, Finlay JL (1998) Current neurosurgical management and the impact of the extent of resection in the treatment of malignantgliomas of childhood: a report of the Children's Cancer Group trial no. CCG-945. J Neurosurg 89(1):52-59 (Pubitemid 28285922)
4. Freeman CR, Kepner J, Kun LE, Sanford RA, Kadota R, Mandell L, Friedman H (2000) A detrimental effect of a combined chemotherapy-radiotherapy approach in children with diffuse intrinsic brain stem gliomas? Int J Radiat Oncol Biol Phys 47(3):561-564 (Pubitemid 30317471)
5. Nightingale SL (1998) From the Food and Drug Administration. JAMA 280(10):872
6. List AF (2007) Lenalidomide-the phoenix rises. New Engl J Med 357(21):2183-2186
7. Melchert M, List A (2007) The thalidomide saga. Int J Biochem Cell Biol 39(7-8):1489-1499 (Pubitemid 47031027)
8. Palumbo A, Dimopoulos M, San Miguel J, Harousseau JL, Attal M, Hussein M, Knop S, Ludwig H, von Lilienfeld-Toal M, Sonneveld P (2009) Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. Blood Rev 23(2):87-93
9. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, Patterson RT, Stirling DI, Kaplan G (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163(1):380-386 (Pubitemid 29295864)
10. Haslett PA, Corral LG, Albert M, Kaplan G (1998) Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 187(11):1885-1892 (Pubitemid 28262451)
11. McHugh SM, Rifkin IR, Deighton J, Wilson AB, Lachmann PJ, Lockwood CM, Ewan PW (1995) The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 99(2):160-167
12. Dredge K, Horsfall R, Robinson SP, Zhang LH, Lu L, Tang Y, Shirley MA, Muller G, Schafer P, Stirling D, Dalgleish AG, Bartlett JB (2005) Orally administered lenalidomide (CC-5013) is antiangiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 69(1-2):56-63 (Pubitemid 40410468)
13. Gandhi AK, Kang J, Naziruddin S, Parton A, Schafer PH, Stirling DI (2006) Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. Leuk Res 30(7):849-858 (Pubitemid 43816707)
14. Drappatz J, Wong ET, Schiff D, Kesari S, Batchelor TT, Doherty L, Lafrankie DC, Ramakrishna N, Weiss S, Smith ST, Ciampa A, Zimmerman J, Ostrowsky L, David K, Norden A, Barron L, Sceppa C, Black PM, Wen PY (2009) A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 73(1):222-227
15. Fine HA, Kim L, Albert PS, Duic JP, Ma H, Zhang W, Tohnya T, Figg WD, Royce C (2007) A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. Clin Cancer Res 13(23):7101-7106 (Pubitemid 350276894)
16. Berg SL, Cairo MS, Russell H, Ayello J, Ingle AM, Lau H, Chen N, Adamson PC, Blaney SM (2011) Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group phase I Consortium Report. J Clin Oncol 29(3):316-323
17. McCully CL, Balis FM, Bacher J, Phillips J, Poplack DG (1990) A rhesus monkey model for continuous infusion of drugs into cerebrospinal fluid. Lab Anim Sci 40(5):520-525 (Pubitemid 20372873)
18. National Research Council (1996) Guide for the care and use of laboratory animals. National Academy Press, Washington
19. Gibladi M, Perrier D (1982) Phamacokinetics, 2nd edn. Marcel Dekker, Inc., New York, Basel
20. Calabrese L, Fleischer AB (2000) Thalidomide: current and potential clinical applications. Am J Med 108(6):487-495 (Pubitemid 30214201)
21. Warren KE, Goldman S, Pollack IF, Fangusaro J, Schaiquevich P, Stewart CF, Wallace D, Blaney SM, Packer R, Macdonald T, Jakacki R, Boyett JM, Kun LE (2011) Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium Study PBTC-018. J Clin Oncol 29(3):324-329
22. Chintagumpala M, Blaney SM, Bomgaars LR, Aleksic A, Kuttesch JF, Klenke RA, Berg SL (2004) Phase I and pharmacokinetic study of thalidomide with carboplatin in children with cancer. J Clin Oncol 22(21):4394-4400 (Pubitemid 41185160)
23. Berg SL, Chamberlain MC (2003) Systemic chemotherapy, intrathecal chemotherapy, and symptom management in the treatment of leptomeningeal metastasis. Curr Oncol Rep 5(1):29-40 (Pubitemid 38898764)
24. Aweeka F, Trapnell C, Chernoff M, Jayewardene A, Spritzler J, Bellibas SE, Lizak P, Jacobson J (2001) Pharmacokinetics and pharmacodynamics of thalidomide in HIV patients treated for oral aphthous ulcers: ACTG protocol 251 AIDS Clinical Trials Group. J Clin Pharmacol 41(10):1091-1097 (Pubitemid 32880137)
25. Figg WD, Raje S, Bauer KS, Tompkins A, Venzon D, Bergan R, Chen A, Hamilton M, Pluda J, Reed E (1999) Pharmacokinetics of thalidomide in an elderly prostate cancer population. J Pharm Sci 88(1):121-125 (Pubitemid 29037378)
26. Piscitelli SC, Figg WD, Hahn B, Kelly G, Thomas S, Walker RE (1997) Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 41(12):2797-2799 (Pubitemid 27524765)
27. Noormohamed FH, Youle MS, Higgs CJ, Kook KA, Hawkins DA, Lant AF, Thomas SD (1999) Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects. AIDS Res Hum Retroviruses 15(12):1047-1052 (Pubitemid 29379799)
28. Blum W, Klisovic RB, Becker H, Yang X, Rozewski DM, Phelps MA, Garzon R, Walker A, Chandler JC, Whitman SP, Curfman J, Liu S, Schaaf L, Mickle J, Kefauver C, Devine SM, Grever MR, Marcucci G, Byrd JC (2010) Dose escalation of lenalidomide in relapsed or refractory acute leukemias. J Clin Oncol 28(33):4919-4925